Zomedica Pharmaceuticals Corp (ZOM)

NYSE

Currency in USD

0.0382

+0.0058(+17.90%)

Real-time Data·12/03

Fair Value

Unlock Value

Day's Range

0.0315

0.0419

52 wk Range

0.0151

0.1952

ZOM Income Statement

Featured here, the Income Statement (earnings report) for Zomedica Pharmaceuticals Corp, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Total Revenues

aa.aa

4.13

18.93

25.19

27.29

Total Revenues Growth

aa.aa

+358.02%

+33.05%

+8.33%

Cost of Revenue

aa.aa

1.08

5.46

7.87

8.2

Gross Profit

aa.aa

3.05

13.47

17.32

19.09

Gross Profit Growth

aa.aa

+341%

+28.59%

+10.21%

Gross Profit Margin %

aa.aa

73.89%

71.15%

68.76%

69.95%

Other Operating Expenses, Total

aa.aa

16.76

24.43

35.39

48.91

54.12

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-15.26%	+45.71%	+44.88%	+38.2%	+10.64%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	7.96	1.58	2.58	5.74	7.27
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	8.8	22.85	32.81	43.17	46.85
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

-16.76

-21.37

-21.92

-31.59

-35.03

Operating Income Growth

aa.aa

+15.26%

-27.49%

-2.57%

-44.1%

-10.88%

EBIT Margin %

aa.aa

-517.15%

-115.81%

-125.43%

-128.38%

Net Interest Expenses

aa.aa

0.03

0.35

2.7

5.28

3.97

Net Interest Expenses Growth

aa.aa

+275.19%

+992.54%

+669.23%

+95.67%

-24.93%

Interest Expense, Total

aa.aa

-0

-0.01

-0

-0.18

Interest And Investment Income

aa.aa

0.03

0.36

2.7

5.46

3.97

Other Non Operating Expenses, Total

aa.aa

0.02

-0.16

-0.07

-0.24

EBT, Excl. Unusual Items

aa.aa

-16.73

-21

-19.38

-26.38

-31.31

Gain (Loss) On Sale Of Assets

aa.aa

-0.18

-0.25

0.02

-0.21

Other Unusual Items, Total

aa.aa

0.53

0.51

EBT, Incl. Unusual Items

aa.aa

-16.91

-20.72

-19.38

-35.86

-47.54

EBT, Incl. Unusual Items Growth

aa.aa

+14.52%

-22.5%

+6.45%

-85.03%

-32.57%

EBT, Incl. Unusual Items Margin

aa.aa

-501.26%

-102.38%

-142.38%

-174.23%

Income Tax Expense

aa.aa

-2.33

-2.37

-1.33

-0.56

Net Income to Company

aa.aa

-16.91

-18.38

-17.02

-34.53

-46.98

Minority Interest

aa.aa

Net Income

aa.aa

-16.91

-18.38

-17.02

-34.53

-46.98

Net Income Growth

aa.aa

+14.52%

-8.71%

+7.45%

-102.93%

-36.07%

Net Income Margin %

aa.aa

-444.81%

-89.88%

-137.1%

-172.19%

Preferred Dividend and Other Adjustments

aa.aa

32.04

Net Income to Common Excl. Extra Items

aa.aa

-16.91

-50.42

-17.02

-34.53

-46.98

Basic EPS - Continuing Operations

aa.aa

-0.05

-0.02

-0.04

-0.05

Basic EPS - Continuing Operations Growth

aa.aa

+75.07%

-13.6%

+67.06%

-102.93%

-36.07%

Diluted EPS - Continuing Operations

aa.aa

-0.05

-0.02

-0.04

-0.05

Diluted EPS - Continuing Operations Growth

aa.aa

+73.68%

-5.43%

+67.06%

-102.93%

-36.07%

Basic Weighted Average Shares Outstanding

aa.aa

364.44

956.53

979.95

Diluted Weighted Average Shares Outstanding

aa.aa

364.44

956.53

979.95

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-16.23

-20.24

-17.88

-25.29

-27.04

EBITDA Growth

aa.aa

+16.77%

-24.64%

+11.63%

-41.46%

-6.91%

EBITDA Margin %

aa.aa

-489.6%

-94.46%

-100.43%

-99.11%

EBIT

aa.aa

-16.76

-21.37

-21.92

-31.59

-35.03

* In Millions of USD (except for per share items)

Nifty 50

24,853.40

-93.10

-0.37%

BSE Sensex

81,583.30

-212.85

-0.26%

Nifty Bank

55,714.15

-230.75

-0.41%

Nifty 50 Futures

24,859.00

-137.20

-0.55%

US 500

5,990.40

-42.7

-0.71%

FTSE 100

8,834.03

-41.19

-0.46%

Dollar Index

98.352

+0.800

+0.82%

Market Movers

Name	Last	Chg. %	Vol.
Vishal Mega Mart	126.77	+1.54%	1.16B
Sterlite Technologies	112.71	+13.41%	147.81M
Happiest Minds	668.45	+11.12%	25.04M
Reliance Industries	1,431.20	-0.46%	10.37M
HDFC Bank	1,929.60	-0.30%	8.49M
Mazagon Dock	3,305.90	+4.43%	6.85M
BSE	2,664.40	-1.22%	6.16M

Name	Last	Chg. %	Vol.
Cinevista Ltd	21.42	+20.00%	567.18K
Raminfo	92.66	+19.99%	53.27K
JMJ Fintech	35.06	+19.99%	500.03K
Cinevista Ltd	21.340	+19.96%	1.41M
Pentagon Rubber	69.50	+19.93%	82.00K
Unishire Urban	2.49	+19.71%	150.00K
KBC Global	0.62	+19.23%	227.04M

Name	Last	Chg. %	Vol.
Triveni Enterprises	1.66	-15.31%	1.39M
Franklin Leasing and Finance	10.680	-12.75%	4.00K
Broach Lifecare Hospital	19.15	-10.93%	12.00K
India Finsec	141.10	-10.41%	41.00
First Custodian Fund India	113.45	-10.00%	2.35K
Helpage Finlease	22.68	-9.96%	36.02K
Zodiac-JRD-MKJ	59.24	-9.78%	81.45K

Trending Stocks

Name	Last	Chg. %	Vol.
Tata Motors	674.75	-1.73%	17.11M
Vishal Mega Mart	126.77	+1.54%	1.16B
Sterlite Technologies	112.71	+13.41%	147.81M
BSE	2,664.40	-1.22%	6.16M
Bajaj Finance	923.00	-1.60%	6.11M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaa	201.03	+44.95%	291.39
A Aaaa A Aaaaaaaaa	63.48	+41.59%	89.88
Aaaa Aaaaaaaaaaaaa	115.50	+39.81%	161.48
A Aa Aa Aaa Aaa A	232.930	+37.84%	321.07
Aa Aaa	232.80	+37.55%	320.22
Aaaaaaaaaaaaaa Aaaa	872.85	+36.20%	1,188.82
Aaaaa A Aaaaaa	716.40	+36.09%	974.95

Name	Last	Upside	Fair Value
Aaaaaaa	201.03	+44.95%	291.39
A Aaaa A Aaaaaaaaa	63.48	+41.59%	89.88
Aaaa Aaaaaaaaaaaaa	115.50	+39.81%	161.48
A Aa Aa Aaa Aaa A	232.930	+37.84%	321.07
Aa Aaa	232.80	+37.55%	320.22
Aaaaaaaaaaaaaa Aaaa	872.85	+36.20%	1,188.82
Aaaaa A Aaaaaa	716.40	+36.09%	974.95

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Zomedica Pharmaceuticals Corp (ZOM)

ZOM Income Statement

Trending Stocks